Figure S5 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis | Synapse
August 4, 2025
Figure S5 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Key Points
PLT012 shows significant potential in enhancing antitumor immunity against liver cancer.
In silico analysis indicates effective targeting of metastatic diseases within liver cancer.
Humanized CD36-blocking antibody demonstrated promising effects in preclinical settings.
Findings could lead to improved treatment options for patients with liver cancer and metastasis.
Abstract
An in silico analysis on POG570 to evaluate the potential of PLT012 in targeting metastatic diseases.